Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials - PubMed (original) (raw)
Review
. 2014 Apr;145(4):779-786.
doi: 10.1378/chest.13-1235.
Affiliations
- PMID: 24202435
- DOI: 10.1378/chest.13-1235
Review
Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials
Daniel R Morales et al. Chest. 2014 Apr.
Abstract
Background: β-Blockers are avoided in asthma over concerns regarding acute bronchoconstriction. Risk is greatest following acute exposure, including the potential for antagonism of β2-agonist rescue therapy.
Methods: A systematic review of databases was performed to identify all randomized, blinded, placebo-controlled clinical trials evaluating acute β-blocker exposure in asthma. Effect estimates for changes in respiratory function, symptoms, and β2-agonist response were pooled using random effects meta-analysis with heterogeneity investigated.
Results: Acute selective β-blockers in the doses given caused a mean change in FEV1 of −6.9% (95% CI, −8.5 to −5.2), a fall in FEV1 of ≥20% in one in eight patients (P=.03), symptoms affecting one in 33 patients (P=.18), and attenuation of concomitant β2-agonist response of −10.2% (95% CI, −14.0 to −6.4). Corresponding values for acute nonselective β-blockers in the doses given were −10.2% (95% CI, −14.7 to −5.6), one in nine patients (P=.02), one in 13 patients (P=.14), and −20.0% (95% CI, −29.4 to −10.7). Following investigation of heterogeneity, clear differences were found for celiprolol and labetalol. A dose-response relationship was demonstrated for selective β-blockers.
Conclusions: Selective β-blockers are better tolerated but not completely risk-free. Risk from acute exposure may be mitigated using the smallest dose possible and β-blockers with greater β1-selectivity. β-Blocker-induced bronchospasm responded partially to β2-agonists in the doses given with response blunted more by nonselective β-blockers than selective β-blockers. Use of β-blockers in asthma could possibly be based upon a risk assessment on an individual patient basis.
Similar articles
- Cardioselective beta-blockers for reversible airway disease.
Salpeter S, Ormiston T, Salpeter E. Salpeter S, et al. Cochrane Database Syst Rev. 2002;(1):CD002992. doi: 10.1002/14651858.CD002992. Cochrane Database Syst Rev. 2002. PMID: 11869646 Updated. Review. - Cardioselective beta-blocker use in patients with reversible airway disease.
Salpeter S, Ormiston T, Salpeter E. Salpeter S, et al. Cochrane Database Syst Rev. 2001;2002(2):CD002992. doi: 10.1002/14651858.CD002992. Cochrane Database Syst Rev. 2001. PMID: 11406056 Free PMC article. Updated. Review. - Cardioselective beta-blockers for reversible airway disease.
Salpeter S, Ormiston T, Salpeter E. Salpeter S, et al. Cochrane Database Syst Rev. 2002;(4):CD002992. doi: 10.1002/14651858.CD002992. Cochrane Database Syst Rev. 2002. PMID: 12519582 Review. - Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.
Salpeter SR, Ormiston TM, Salpeter EE. Salpeter SR, et al. Ann Intern Med. 2002 Nov 5;137(9):715-25. doi: 10.7326/0003-4819-137-9-200211050-00035. Ann Intern Med. 2002. PMID: 12416945 - Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials.
Morales DR, Dreischulte T, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Morales DR, et al. Br J Clin Pharmacol. 2016 Sep;82(3):814-22. doi: 10.1111/bcp.13006. Epub 2016 Jun 17. Br J Clin Pharmacol. 2016. PMID: 27161880 Free PMC article. Review.
Cited by
- Predictors of Asthma Control by Stepwise Treatment in Elderly Asthmatic Patients.
Ban GY, Ye YM, Lee Y, Kim JE, Nam YH, Lee SK, Kim JH, Jung KS, Kim SH, Park HS; Premier Researchers Aiming New Era in Asthma and Allergic Diseases (PRANA) Study Group. Ban GY, et al. J Korean Med Sci. 2015 Aug;30(8):1042-7. doi: 10.3346/jkms.2015.30.8.1042. Epub 2015 Jul 15. J Korean Med Sci. 2015. PMID: 26240480 Free PMC article. Clinical Trial. - The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports.
Bennett M, Chang CL, Tatley M, Savage R, Hancox RJ. Bennett M, et al. ERJ Open Res. 2021 Mar 1;7(1):00801-2020. doi: 10.1183/23120541.00801-2020. eCollection 2021 Jan. ERJ Open Res. 2021. PMID: 33681344 Free PMC article. Review. - Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study.
Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Morales DR, et al. BMC Med. 2017 Jan 27;15(1):18. doi: 10.1186/s12916-017-0781-0. BMC Med. 2017. PMID: 28126029 Free PMC article. - Diving with hypertension and antihypertensive drugs.
Westerweel PE, Rienks R, Sakr A, Taher A. Westerweel PE, et al. Diving Hyperb Med. 2020 Mar 31;50(1):49-53. doi: 10.28920/dhm50.1.49-53. Diving Hyperb Med. 2020. PMID: 32187618 Free PMC article. Review. - The association between glaucoma and risk of depression: a nationwide population-based cohort study.
Chen YY, Lai YJ, Wang JP, Shen YC, Wang CY, Chen HH, Hu HY, Chou P. Chen YY, et al. BMC Ophthalmol. 2018 Jun 22;18(1):146. doi: 10.1186/s12886-018-0811-5. BMC Ophthalmol. 2018. PMID: 29929494 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical